A two-week course of an inhaled peptide did not touch lung function in 24 people with idiopathic pulmonary fibrosis. That was never the point of a 14-day study. What it did touch was the set of molecular signals that drive the scarring, and it turned several of them down.
The drug is LTI-03, from Rein Therapeutics ↗ (the company formerly called Aileron). It is a synthetic seven-amino-acid peptide copied from a stretch of caveolin-1, a structural protein of the cell membrane that is depleted in fibrotic lung tissue. The idea behind the molecule is unusual for the field. Most antifibrotic programs try to block a single profibrotic pathway. LTI-03 is designed to do two things at once: keep the alveolar epithelial cells that line the air sacs alive, while quieting the signaling that turns fibroblasts into scar-laying myofibroblasts. In idiopathic pulmonary fibrosis, or IPF, the lung slowly replaces working gas-exchange tissue with stiff collagen, and the epithelial cells that should repair the surface die off instead. A drug that protects the lining and calms the scarring at the same time is trying to fix both halves of that loop.
The results were published in Nature Communications ↗. The trial was a Phase 1b, randomized, double-blind, placebo-controlled dose-escalation study. Twenty-four patients with IPF were split into two sequential groups. Each group got either LTI-03 or placebo in a 3-to-1 ratio, inhaled once a day for 14 days, at 5 mg a day in the first group and 10 mg a day in the second. Twelve of the patients were on a background antifibrotic already, so the peptide was being tested on top of existing standard-of-care rather than in a vacuum.
On safety, which is what a Phase 1b exists to establish, the peptide was clean. No patient stopped the drug because of a side effect. The adverse events that did occur were mild or moderate, and the most common one tied to the drug was cough, which is unsurprising for anything inhaled into an already-damaged lung. There was no sign of airway narrowing, either by how patients felt or by spirometry, the standard breathing test that measures how much and how fast air moves out of the lungs.
The reason the study is worth reporting is the biomarker readout. The researchers went in with a bronchoscope and brushed cells directly from deep in the airways, then measured the profibrotic proteins those cells were making. Both doses significantly lowered IL-11 and TSLP, two signaling proteins that push lung cells toward scarring and inflammation, compared with placebo. The higher 10 mg dose went further, significantly reducing COL1A1 (the gene product that is literally the backbone of type 1 collagen, the material scar tissue is made of), plus CXCL7 and galectin-7, two more proteins linked to fibrotic remodeling. There was also a downward trend in surfactant protein D in the blood, a marker that tends to rise as alveolar cells are damaged, at the 10 mg dose. Reading several of the drivers of scarring move in the right direction, in cells pulled straight from the target tissue, is a more direct mechanistic signal than most early lung trials get.
The honest caveats are large and worth stating plainly. This is 24 people over 14 days. The endpoints are molecules in airway cells, not forced vital capacity, the lung-volume measure that regulators actually approve IPF drugs on, and not survival or exacerbation rate, which are what patients care about. Biomarker moves this early have a long history of not surviving contact with a real efficacy trial. The mechanism is also a departure from the two approved IPF drugs, pirfenidone and nintedanib, both of which slow decline without stopping it and both of which many patients tolerate poorly. A protect-the-lining approach could in principle complement them, but the trial was not built to prove that.
What LTI-03 shares with a different antifibrotic peptide reported this week, a self-assembling net designed to soak up the scarring signal TGF-beta in tendons ↗, is the shift in strategy. Both are peptides aimed at the tissue-repair machinery rather than at killing a runaway cell population. The real test for LTI-03 is already enrolling. A Phase 2 trial called RENEW is set up to run the peptide longer, in more patients, and to measure whether the biomarker signal turns into preserved lung function. Until that reads out, the fair summary is that a two-week inhaled peptide moved the chemistry of fibrosis in the right direction and did nothing alarming, which is exactly the result that earns a Phase 2 and settles nothing on its own.